Literature DB >> 28650454

Analysis of hematopoietic recovery after autologous transplantation as method of quality control for long-term progenitor cell cryopreservation.

J Pavlů1,2, H W Auner1,2, R M Szydlo2, B Sevillano1, R Palani1, F O'Boyle2, A Chaidos1,2, C Jakob1,2, E Kanfer1,2, D MacDonald1,2, D Milojkovic1,2, A Rahemtulla1,2, A Bradshaw1, E Olavarria1,2, J F Apperley1,2, O M Pello1,2.   

Abstract

Hematopoietic precursor cells (HPC) are able to restore hematopoiesis after high-dose chemotherapy and their cryopreservation is routinely employed prior to the autologous hematopoietic cell transplantation (AHCT). Although previous studies showed feasibility of long-term HPC storage, concerns remain about possible negative effects on their potency. To study the effects of long-term cryopreservation, we compared time to neutrophil and platelet recovery in 50 patients receiving two AHCT for multiple myeloma at least 2 years apart between 2006 and 2016, using HPC obtained from one mobilization and collection attempt before the first transplant. This product was divided into equivalent fractions allowing a minimum of 2 × 106 CD34+ cells/kg recipient's weight. One fraction was used for the first transplant after median storage of 60 days (range, 17-165) and another fraction was used after median storage of 1448 days (range, 849-3510) at the second AHCT. Neutrophil recovery occurred at 14 days (median; range, 11-21) after the first and 13 days (10-20) after the second AHCT. Platelets recovered at a median of 16 days after both procedures. Considering other factors, such as disease status, conditioning and HPC dose, this single institution data demonstrated no reduction in the potency of HPC after long-term storage.

Entities:  

Mesh:

Year:  2017        PMID: 28650454     DOI: 10.1038/bmt.2017.113

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  5 in total

1.  Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics.

Authors:  Sandhya R Panch; Sandeep K Srivastava; Nasha Elavia; Andrew McManus; Shutong Liu; Ping Jin; Steven L Highfill; Xiaobai Li; Pradeep Dagur; James N Kochenderfer; Terry J Fry; Crystal L Mackall; Daniel Lee; Nirali N Shah; David F Stroncek
Journal:  Mol Ther       Date:  2019-05-30       Impact factor: 11.454

2.  How old is too old? In vivo engraftment of human peripheral blood stem cells cryopreserved for up to 18 years - implications for clinical transplantation and stability programs.

Authors:  John Underwood; Mahvish Rahim; Carijo West; Rebecca Britton; Elaine Skipworth; Vicki Graves; Steven Sexton; Hillary Harris; Dave Schwering; Anthony Sinn; Karen E Pollok; Kent A Robertson; W Scott Goebel; Kerry M Hege
Journal:  World J Stem Cells       Date:  2020-05-26       Impact factor: 5.326

3.  A retrospective review of infections and outcomes within 100 days of hematopoietic stem cell transplantation: insights from a new transplant program in the Philippines.

Authors:  Jia An G Bello; Angela Beatriz Cruz; Ma Patricia Virata; Alma Calavera; Cybele L Abad
Journal:  IJID Reg       Date:  2022-03-20

4.  The Functional Effect of Repeated Cryopreservation on Transduced CD34+ Cells from Patients with Thalassemia.

Authors:  Garyfalia Karponi; Penelope-Georgia Papayanni; Fani Zervou; Asimina Bouinta; Achilles Anagnostopoulos; Evangelia Yannaki
Journal:  Hum Gene Ther Methods       Date:  2018-08-30       Impact factor: 2.396

5.  Impact of Cryopreservation of Peripheral Blood Stem Cells (PBSC) in Transplantation from Matched Unrelated Donor (MUD).

Authors:  Gabriele Facchin; Chiara Savignano; Marta Lisa Battista; Miriam Isola; Maria De Martino; Giuseppe Petruzzellis; Chiara Rosignoli; Umberto Pizzano; Michela Cerno; Giulia De Cecco; Antonella Bertone; Giovanni Barillari; Renato Fanin; Francesca Patriarca
Journal:  J Clin Med       Date:  2022-07-15       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.